These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 17606734)

  • 1. A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses.
    Durso RJ; Andjelic S; Gardner JP; Margitich DJ; Donovan GP; Arrigale RR; Wang X; Maughan MF; Talarico TL; Olmsted RA; Heston WD; Maddon PJ; Olson WC
    Clin Cancer Res; 2007 Jul; 13(13):3999-4008. PubMed ID: 17606734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer.
    Slovin SF; Kehoe M; Durso R; Fernandez C; Olson W; Gao JP; Israel R; Scher HI; Morris S
    Vaccine; 2013 Jan; 31(6):943-9. PubMed ID: 23246260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen.
    Schroers R; Shen L; Rollins L; Xiao Z; Sonderstrup G; Slawin K; Huang XF; Chen SY
    Clin Cancer Res; 2003 Aug; 9(9):3260-71. PubMed ID: 12960111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.
    Vittes GE; Harden EL; Ottensmeier CH; Rice J; Stevenson FK
    Eur J Immunol; 2011 Aug; 41(8):2447-56. PubMed ID: 21604260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity.
    Avogadri F; Merghoub T; Maughan MF; Hirschhorn-Cymerman D; Morris J; Ritter E; Olmsted R; Houghton AN; Wolchok JD
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients.
    Harada M; Matsueda S; Yao A; Ogata R; Noguchi M; Itoh K
    Oncol Rep; 2004 Sep; 12(3):601-7. PubMed ID: 15289844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector.
    Williams BJ; Bhatia S; Adams LK; Boling S; Carroll JL; Li XL; Rogers DL; Korokhov N; Kovesdi I; Pereboev AV; Curiel DT; Mathis JM
    PLoS One; 2012; 7(10):e46981. PubMed ID: 23056548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
    Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
    Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes.
    Mincheff M; Zoubak S; Altankova I; Tchakarov S; Makogonenko Y; Botev C; Ignatova I; Dimitrov R; Madarzhieva K; Hammett M; Pomakov Y; Meryman H; Lissitchkov T
    Cancer Gene Ther; 2003 Dec; 10(12):907-17. PubMed ID: 14712317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses.
    Ferraro B; Cisper NJ; Talbott KT; Philipson-Weiner L; Lucke CE; Khan AS; Sardesai NY; Weiner DB
    Hum Vaccin; 2011; 7 Suppl():120-7. PubMed ID: 21266849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical nature and mapping of PSMA epitopes recognized by human antibodies induced after immunization with gene-based vaccines.
    Todorova K; Zoubak S; Mincheff M; Kyurkchiev S
    Anticancer Res; 2005; 25(6C):4727-32. PubMed ID: 16334167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients.
    Kobayashi K; Noguchi M; Itoh K; Harada M
    Cancer Sci; 2003 Jul; 94(7):622-7. PubMed ID: 12841872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles.
    Goldberg SM; Bartido SM; Gardner JP; Guevara-Patiño JA; Montgomery SC; Perales MA; Maughan MF; Dempsey J; Donovan GP; Olson WC; Houghton AN; Wolchok JD
    Clin Cancer Res; 2005 Nov; 11(22):8114-21. PubMed ID: 16299244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy.
    Ma Q; Safar M; Holmes E; Wang Y; Boynton AL; Junghans RP
    Prostate; 2004 Sep; 61(1):12-25. PubMed ID: 15287090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and preclinical evaluation of an alphavirus replicon vaccine for influenza.
    Hubby B; Talarico T; Maughan M; Reap EA; Berglund P; Kamrud KI; Copp L; Lewis W; Cecil C; Norberg P; Wagner J; Watson A; Negri S; Burnett BK; Graham A; Smith JF; Chulay JD
    Vaccine; 2007 Nov; 25(48):8180-9. PubMed ID: 17961878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded.
    Todorova K; Ignatova I; Tchakarov S; Altankova I; Zoubak S; Kyurkchiev S; Mincheff M
    Cancer Immun; 2005 Jan; 5():1. PubMed ID: 15641767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice.
    White LJ; Parsons MM; Whitmore AC; Williams BM; de Silva A; Johnston RE
    J Virol; 2007 Oct; 81(19):10329-39. PubMed ID: 17652394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA.
    Kuratsukuri K; Sone T; Wang CY; Nishisaka N; Jones RF; Haas GP
    Int J Cancer; 2002 Nov; 102(3):244-9. PubMed ID: 12397643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo.
    Medin JA; Liang SB; Hou JW; Kelley LS; Peace DJ; Fowler DH
    Cancer Gene Ther; 2005 Jun; 12(6):540-51. PubMed ID: 15678150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.